Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

Core Insights - Stoke Therapeutics, Inc. presented two-year data from the FALCON study, focusing on Autosomal Dominant Optic Atrophy (ADOA) [1] - The study involved 47 participants and was showcased at the 2025 American Academy of Ophthalmology Annual Meeting [1] Company Overview - Stoke Therapeutics is a biotechnology company that aims to restore protein expression through RNA medicines [1] - The company is dedicated to leveraging the body's potential in its therapeutic approaches [1] Study Details - The FALCON study is a prospective natural history study specifically targeting individuals with ADOA [1] - The results from this study provide significant insights into the condition of ADOA [1]